z-logo
Premium
Laser therapy of telangiectatic leg veins: clinical evaluation of the 810 nm diode laser
Author(s) -
Varma S.,
Lanigan S. W.
Publication year - 2000
Publication title -
clinical and experimental dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.587
H-Index - 78
eISSN - 1365-2230
pISSN - 0307-6938
DOI - 10.1046/j.1365-2230.2000.00679.x
Subject(s) - medicine , sclerotherapy , telangiectasia , visual analogue scale , laser therapy , surgery , intense pulsed light , purpura (gastropod) , laser , dermatology , physics , optics , ecology , biology
Telangiectatic leg veins (TLV) are experienced by millions of women and men. As they cause significant cosmetic embarrassment, many women seek effective treatment. Options include sclerotherapy and treatment with different lasers. We investigated the safety and efficacy of an 810‐nm diode laser in the treatment of TLV. Ten females had treatment to a ≥ 25 cm 2 area of TLV four times at 4‐weekly intervals at 25–35 W, 0.1 s duration, 0.5 s interval and a 5‐mm circular spot size (fluence of 12.7–17.8 J/cm 2 ). Assessment of response was performed 4 weeks after the final treatment and patients were asked to complete a questionnaire requesting information regarding the treatment. No statistically significant clearing of the leg veins was demonstrated although some improvement was noted in individual patients. Side‐effects were negligible, consisting of discomfort or mild pain. There was no scarring, purpura or pigment alteration. A visual analogue scale questionnaire (0–10) revealed that patients found the treatment acceptable (range, 4–10). Overall difference as assessed by the patients ranged from 0 to 8.4 and degree of satisfaction with the treatment from 0 to 9.8. Currently, the treatment of choice for TLV remains sclerotherapy. Our results suggest that the 810‐nm diode laser is safe and well tolerated. Further research could establish whether effectiveness can be improved with higher fluences or in combination with sclerotherapy.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here